Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 22,004 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
Interventions: Obinutuzumab, Liposomal ARA-C, Ifosfamide, Carboplatin, Etoposide; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 3 Years to 31 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Substance Use Disorder
Interventions: Personal Causal Model + Personalized Feedback; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
Interventions: Isatuximab, Belantamab mafodotin, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Nutrition, Diet Interventions
Interventions: Control label, Added sugar warning; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 543 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: COPD, Chronic Musculoskeletal Pain
Interventions: Every Step Counts-Tai Chi, Usual Care; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 100 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Uveal Melanoma
Interventions: ZIV-Aflibercept, Cemiplimab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 4
States / cities: Los Angeles, California • Tampa, Florida • Chicago, Illinois + 1 more

Conditions: Epilepsy
Interventions: Mangafodipir, Gadolinium; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension (HTN), Preeclampsia, Hypertensive Disorders of Pregnancy (HDP)
Interventions: Coaching application, Home-based blood pressure monitoring, WebMD; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Barrett Esophagus, Gastroesophageal Reflux, Esophageal Adenocarcinoma
Interventions: EsoCheck, EsoGuard; Device · Diagnostic Test
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 50 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Aurora, Colorado • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more

Conditions: Rotator Cuff Tears of the Shoulder
Interventions: Integrity Implant System; Device
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Gilbert, Arizona • Pomona, California • Tampa, Florida + 6 more

Conditions: Mental Health
Interventions: Great Life Mentoring; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 9 Years to 16 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Spatial Navigation
Interventions: Active 10-Hz TMS to the parietal cortex, Active single pulse TMS to the parietal cortex, Sham 10-Hz TMS to the right parietal cortex, Sham single-pulse rTMS the rigt parietal cortex; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Acupressure Therapy, Acupressure Therapy - placebo, Acupressure Therapy - self-administered, Health Promotion and Education, Survey Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Formula Dependent Children 1 to 2 Years of Age
Interventions: Kate Farms Standard 1.2 or Peptide 1.0; Dietary Supplement
Lead sponsor: Kate Farms Inc; Industry
Eligibility: 12 Months to 17 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Olfactory Neuroblastoma, Esthesioneuroblastoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 120 Years
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: SB Intervention; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 55 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Autism
Interventions: Parent Training; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 12 Months to 36 Months
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Breast Cancer, Breast Neoplasm, Breast Tumor, Cancer of the Breast
Interventions: Proton Radiotherapy; Radiation
Lead sponsor: Proton Collaborative Group; Network
Eligibility: 50 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2035
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Diego, California • Warrenville, Illinois + 6 more

Conditions: Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer
Interventions: PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D); Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions: Venetoclax, Azacitadine, Vorinostat, Cytarabine, Fludarabine, Filgrastim; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 1 Year to 25 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Vulvar Intraepithelial Neoplasia, HPV-Independent, Vulvar Squamous Cell Carcinoma, Vulvar Squamous Intraepithelial Lesion, HPV-Associated
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more

Conditions: Primary Ciliary Dyskinesia, Healthy
Interventions: Lung Function Testing, Phlebotomy, Allergy skin prick testing, Methacholine Challenge; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 6 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prostate Cancer
Interventions: Radiation, MRI, Androgen Deprivation Therapy; Radiation · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Personalized Approach to Healthy Use and Recovery (PATH) Trial

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Impacts of Sugar Warnings on Weight Bias

The Effect of a Technology-Mediated Integrated Walking and Tai Chi Intervention on Physical Function in Veterans With COPD and Chronic Musculoskeletal Pain

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Mobile Health Program for Post-Preeclampsia Hypertension

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

Integrity Implant System Post Market Clinical Follow-Up Study

Study of Mental Health and Relationships

Modulating Goal-directed Navigation Using Noninvasive Brain Stimulation

Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy

Growth and Tolerance of Plant-based Enteral Formulas in Children Ages 12-17 Months.

A Natural History Study of Children and Adults With Olfactory Neuroblastoma

Glucose and Activity Tracking for Sedentary Behavior Interventions in Older People With Type 2 Diabetes (TRACK T2D)

Family-Centered Implementation of Parent Training for Autistic Toddlers in Early Intervention

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Evaluation of a Point-of-Care, AI-Powered Spectroscopy Device for Triage of Suspicious Vulvar Lesions: A Pilot Study

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life